About the Authors
- Xing Xian Yu
-
* E-mail: xyu@isisph.com
Affiliation Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California, United States of America
- Lynnetta M. Watts
-
Affiliation Department of Clinical Development, Isis Pharmaceuticals Inc., Carlsbad, California, United States of America
- Vara Prasad Manchem
-
Affiliation Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California, United States of America
- Kaushik Chakravarty
-
Affiliation Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California, United States of America
- Brett P. Monia
-
Affiliation Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California, United States of America
- Michael L. McCaleb
-
Affiliation Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California, United States of America
- Sanjay Bhanot
-
Affiliation Department of Clinical Development, Isis Pharmaceuticals Inc., Carlsbad, California, United States of America
Competing Interests
All authors are employeesand sharesholders of Isis Pharmaceuticals, Inc., the funder of this study. Isis Pharmaceuticals, Inc. has patent applications for FGFR4 ASO, and is developing human FGFR4 ASO, which was not used in the studies described in this manuscript, for the treatment of obesity. The current patent applications are: US2010-0292140, WO 2012/174476 and Europe 2215102. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: XXY BPM MLM SB. Performed the experiments: XXY LMW VPM KC. Analyzed the data: XXY LMW VPM KC. Contributed reagents/materials/analysis tools: XXY LMW VPM. Wrote the paper: XXY MLM SB.